Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment
NCT02711813 · Theramab LLC · PHASE2 · terminated · last registry update 2018-05-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Administrative reasons” | – | Registry record, Theramab LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD28 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-01-04Results posted on the registry: Bristol-Myers Squibb, BMS-931699 + Placebo matching BMS-931699 (NCT02265744)
- 2018-10-04Results posted on the registry: Bristol-Myers Squibb, BMS-931699 + BMS-986142 (NCT02843659)
- 2018-10-04Also stopped (terminated): Bristol-Myers Squibb, BMS-931699 + BMS-986142 (NCT02843659)
- 2017-12-20Also stopped (terminated): Bristol-Myers Squibb, BMS-931699 (NCT03058822)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision